A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.
By U. Veronesi, G. Paganelli, G. Viale, A. Luini, S. Zurrida, V. Galimberti, M. Intra, P. Veronesi, C. Robertson, P. Maisonneuve and 4 more. New England Journal of Medicine, 2003
2,169 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/afaa30d7db7d3a032578748defdab9007f89a368
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Surgery
Citations in the corpus
- Sentinel Lymph Node Dissection With and Without Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial (2011, neutral): “Age, median (range), y 56 (24-92) 54 (25-90)”
- Lymphatic mapping and sentinel lymph node biopsy in early‐stage breast carcinoma (2006, background): “To our knowledge, only one prospective, randomized, controlled trial has been reported to date with relatively short-term follow-up in a small number of carefully selected patients.(15) Although several additional trials are underway, each has limitations in the questions addressed and the populatio”
- Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. (2014, background): “At the time of publication, there was only one published randomized clinical trial (RCT), by Veronesi et al.1 There were no axillary recurrences in patients who had tumor-free nodes and did not undergo axillary lymph node dissection (ALND), and the short-term survival was similar for those with tumo”
- American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. (2005, methodology): “To date, only one prospective randomized trial has been published in which SNB was compared with formal axillary dissection.(10) Veronesi et al randomly assigned 516 patients with tumors of 2 cm or less to either SNB and ALND or SNB followed by axillary dissection only if the SLN contained metastase”
- Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression (2007, background): “During breast carcinogenesis, the presence of metastatic mammary epithelial cells in sentinel lymph nodes draining the primary tumor represents the strongest prognostic indicator for disease progression and overall patient outcome [49-51].”
- Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. (2013, methodology): “·· Level III-2 Veronesi et al (2003);74 Italy 516 patients (grade 1–3): 257 in the axillary-dissection group (SLNB+total axillary dissection) and 259 in the sentinel-node group (SLNB+axillary dissection if SLNB contained metastases); 100 patients in each study group was used to describe side-eff…”
- Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial (2013, methodology): “Eligibility and Exclusion Criteria We enrolled women aged 18 years or older who (1) had histologically proven clinical stage T0 through T4, N1 through N2, M0 primary invasive breast cancer according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, sixth edition (Table 1), (2) ”